According to filings with the U.S. Securities and Exchange Commission, IGM Biosciences is raising $22,500,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Misbah Tahir played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About IGM Biosciences
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma.

To learn more about IGM Biosciences, visit http://www.igmbio.com/

Contact:
Misbah Tahir, Chief Financial Officer
650-965-7873
https://www.linkedin.com/in/misbahtahir/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.